Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report.
Curr Oncol
; 31(7): 4015-4021, 2024 Jul 14.
Article
en En
| MEDLINE
| ID: mdl-39057170
ABSTRACT
A 48-year-old woman without obvious environmental risk factors was diagnosed with metastatic urothelial carcinoma harboring a mutation in EGFR typical of driver mutations for non-small cell lung cancer. Within a year, her cancer progressed on four standard therapies for urothelial cancer, including cancer in lungs, liver, bone, and brain. As fifth-line therapy, she received osimertinib, leading to a complete response in the brain and improvement elsewhere, and the cancer remained controlled for six months. Targeted therapy for rare driver mutations can be effective in urothelial cancer and should be considered prior to exhausting standard therapies.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Acrilamidas
/
Receptores ErbB
/
Compuestos de Anilina
/
Mutación
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Curr Oncol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos